As IP chemotherapy is required to increase the concentration of drugs in peritoneal tumors, the intra-abdominal administration of amido-bridged nucleic acid-modified anti-SYT13 ASOs represents a promising strategy for treating peritoneal metastasis of gastric cancer [27]. This evidence concerns the gene SYT13 and gastric cancer.